Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Helicobacter pylori eradication rate following first line non-bismuth quadruple therapy regimen in Tunisian patients: the HPERAD study.

BMC infectious diseases·2025

Same author

EncephalApp Stroop Test for covert hepatic encephalopathy screening in Tunisian cirrhotic patients.

F1000Research·2023

Same author

Comparison between signet-ring cell carcinoma and non-signet-ring cell carcinoma of the stomach: clinicopathological parameters, epidemiological data, outcome, and prognosis-a cohort study of 123 patients from a non-endemic country.

World journal of surgical oncology·2022

Same author

Clinical practice standards for colonoscopy.

La Tunisie medicale·2022

Same author

Gastric polyps: a 10-year analysis of 18,496 upper endoscopies.

BMC gastroenterology·2022

Same author

Primary gastric squamous cell carcinoma with a bilio-gastric fistula and Krukenberg syndrome.

Clinical case reports·2021

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Ciclosporin for severe refractory colitis.

Asma Ouakaa-Kchaou¹, Dalila Gargouri, Hela Elloumi

¹Service de gastro-entérologie, hôpital Habib Thameur.

La Tunisie Medicale

|June 3, 2010

Summary

Ciclosporin (CSA) offers a viable short-term alternative to colectomy for severe refractory colitis. While not all patients maintain benefits, over half avoid surgery long-term with careful monitoring and optimized dosing.

Related Experiment Videos

Last Updated: Jun 12, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Area of Science:

Gastroenterology
Immunosuppressive Therapy
Inflammatory Bowel Disease

Background:

Severe steroid-refractory colitis often necessitates surgical intervention.
Intravenous ciclosporin presents a rapidly effective alternative, but its use is debated due to adverse effects and long-term efficacy concerns.

Purpose of the Study:

To review the clinical pharmacology of ciclosporin in severe refractory colitis.
To outline indications, dosing, monitoring strategies, and adverse event profiles.
To assess ciclosporin's role as a bridge therapy.

Main Methods:

Comprehensive literature review.

Main Results:

Toxicity primarily involves opportunistic infections, renal, and neurotoxicity.
Lower doses, oral microemulsion, or corticosteroid-free monotherapy can mitigate risks.
Ciclosporin is effective as a short-term bridge to maintenance therapies like azathioprine or 6-mercaptopurine.

Conclusions:

Ciclosporin is a viable alternative to emergency colectomy for severe ulcerative colitis in the short term.
Over half of patients may avoid colectomy long-term.
Careful patient selection, monitoring, lower doses, and oral administration enhance safety and efficacy.